Does Aminocaproic Acid Interact with Anti Inhibitor Coagulant Complex?
Aminocaproic Acid and Anti Inhibitor Coagulant Complex have a major drug interaction according to U.S. FDA drug labeling data. Systemic antifibrinolytic; increased risk of thrombotic events. Use not recommended within 6-12 hours after FEIBA administration. The mechanism involves antifibrinolytic mechanism may increase thrombotic risk with feiba. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Aminocaproic Acid and Anti Inhibitor Coagulant Complex occurs because antifibrinolytic mechanism may increase thrombotic risk with feiba. Clinically, this means systemic antifibrinolytic; increased risk of thrombotic events. use not recommended within 6-12 hours after feiba administration. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Aminocaproic Acid and your doctor is considering prescribing Anti Inhibitor Coagulant Complex (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider